Ardsley Advisory Partners’s Gilead Sciences GILD Stock Holding History

Ardsley Advisory Partners’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-25,000	Closed	-$2.03M	–	155
2017 Q3	$2.03M	Sell	25,000 -100,000	-80%	-$7.65M	0.27%	65
2017 Q2	$8.85M	Hold	125,000	–	–	1.38%	26
2017 Q1	$8.49M	Sell	125,000 -275,000	-69%	-$19.3M	1.32%	25
2016 Q4	$28.6M	Buy	400,000 +300,000	+300%	+$22.3M	4.74%	3
2016 Q3	$7.91M	Buy	+100,000	New	+$8.12M	1.25%	28
2015 Q2	–	Sell	-150,000	Closed	-$14.7M	–	189
2015 Q1	$14.7M	Buy	+150,000	New	+$15.2M	2.05%	14
2014 Q4	–	Sell	-10,000	Closed	-$1.06M	–	214
2014 Q3	$1.06M	Sell	10,000 -150,000	-94%	-$14.7M	0.14%	69
2014 Q2	$13.3M	Buy	160,000 +150,000	+1,500%	+$11.7M	1.69%	16
2014 Q1	$709K	Buy	+10,000	New	+$784K	0.11%	105

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ardsley Advisory Partners's GILD Position: Q4 2016 in Review

Ardsley Advisory Partners sold out of Gilead Sciences (GILD) in Q4 2016, closing a stake of 4,000 shares — an estimated $297K sold.

Ardsley Advisory Partners first reported a position in GILD in Q2 2013 and held it in 13 quarters. The position peaked at $72.5M in Q3 2014. 1,573 funds tracked by Wall St. Rank hold GILD as of Q4 2016.

Ardsley Advisory Partners reported no remaining Gilead Sciences position as of Q4 2016 after selling out during the quarter.
Ardsley Advisory Partners sold 4,000 Gilead Sciences shares in Q4 2016, an estimated $297K.
Ardsley Advisory Partners first reported a position in Gilead Sciences in Q2 2013 and held it in 13 quarters.
Ardsley Advisory Partners's Gilead Sciences position peaked at $72.5M in Q3 2014.
1,573 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2016.

Based on Ardsley Advisory Partners's 13F filing for Q4 2016, filed 14 Feb 2017.